FDA Expands Use of Three Cystic Fibrosis Medications
The Food and Drug Administration (FDA) has expanded the approval of Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor; Vertex),...
MHRA approves Polyphor’s phase 1 trial of novel inhaled antibiotic
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Swiss biotech Polyphor’s first-in-human phase I study...
Antifungal drug improves key cystic fibrosis biomarkers in clinical study
A drug widely used to treat fungal infections improved key biomarkers in lung tissue cultures as well as in the noses of patients with...
Potential Antibiotic Appears to Effectively Treat M. abscessus Infections
A newly developed antibiotic, called T405, appears to effectively kill Mycobacteroides abscessus, a difficult-to-treat bacteria that can...
Production Increases for Pyocin S5, Potential Antibiotic for Treating Lung Disease
Project GAIA, establishing a large-scale manufacturing process for Pyocin S5, an investigational antibiotic for the treatment of lung...
Antifungal drug improves key cystic fibrosis biomarkers in clinical study
CHICAGO, Dec. 18 (Xinhua) -- A drug widely used to treat fungal infections improved key biomarkers in lung tissue cultures as well as in...